Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group

Lancet. 1999 Jul 10;354(9173):130-1. doi: 10.1016/s0140-6736(99)02015-2.

Abstract

Combined chemotherapy for early breast cancer with cyclophosphamide, methotrexate, and fluorouracil has low associated mortality, but related deaths were seen among women aged 65 years or older in International Breast Cancer Study Group trials.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / mortality*
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Cyclophosphamide / adverse effects
  • Female
  • Fluorouracil / adverse effects
  • Humans
  • Methotrexate / adverse effects
  • Middle Aged
  • Postmenopause
  • Premenopause

Substances

  • Cyclophosphamide
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • CMF regimen